Meningococcal serogroup B disease in Turkey: A guess or reality?

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 6, 2014, Pages 1721-1724

  Bakir, Mustafa ^a  

^a MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Diseases; Epidemiology; Invasive; Meningococcal; Serogroup B; Surveillance; Turkey; Vaccine

Indexed keywords

MENINGOCOCCUS VACCINE;

BACTERIAL STRAIN; DISEASE SURVEILLANCE; GEOGRAPHIC DISTRIBUTION; HAEMOPHILUS INFLUENZAE; HEALTH PROGRAM; HUMAN; IMMUNIZATION; MENINGOCOCCOSIS; NONHUMAN; PATHOGEN LOAD; POLYMERASE CHAIN REACTION; REVIEW; STREPTOCOCCUS PNEUMONIAE; TURKEY (REPUBLIC); WORLD HEALTH ORGANIZATION; ISOLATION AND PURIFICATION; MENINGITIS, MENINGOCOCCAL; MICROBIOLOGY; NEISSERIA MENINGITIDIS; PREVALENCE; SEPSIS; TURKEY;

HUMANS; MENINGITIS, MENINGOCOCCAL; NEISSERIA MENINGITIDIS, SEROGROUP B; PREVALENCE; SEPSIS; TURKEY;

EID: 84905668340     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.28438     Document Type: Review

References (23)

1. World Health Organisation (WHO). Control of epidemic meningococcal disease. WHO practical guidelines. 2nd edition. [cited 2013 Feb]. Available from: http://www.who.int/csr/resources/publications/meningitis/WHO-EMC-BAC-98-3- EN/en/.
2. World Health Organisation. Meningococcal vaccines: WHO position paper, November 2011. Wkly Epidemiol Rec 2011; 86:521-39; PMID:22128384
3. Khatami A, Pollard AJ. The epidemiology of meningococcal disease and the impact of vaccines. Expert Rev Vaccines 2010; 9:285-98; PMID:20218857; http://dx.doi.org/10.1586/erv.10.3
4. Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10:317-28; PMID:20417414; http://dx.doi.org/10.1016/S1473-3099(10)70048-7
5. European Centre for Disease Prevention and Control. Annual epidemiological report 2011 - Reporting on 2009 surveillance data and 2010 epidemic intelligence data. [cited June 1013]. Available from: http://ecdc.europa.eu/en/publications/Publications/1111-SUR-Annual- Epidemiologica l-Repor t-on-Communicable-Diseases-in-Europe.pdf.
6. Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine 2009; 27(Suppl 2):B51-63; PMID:19477562; http://dx.doi.org/10. 1016/j.vaccine.2009.04.063
7. Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM. Meningococcal disease. N Engl J Med 2001; 344:1378-88; PMID:11333996; http://dx.doi.org/10.1056/NEJM200105033441807
8. European Centre for Disease Prevention and Control. Surveillance of invasive bacterial diseases in Europe 2008/2009. [cited 2013 June]. Available from: http://ecdc.europa.eu/en/publications/Publications/1107-SUR-IBD-2008-09. pdf.
9. Borrow R, Abad R, Trotter C, van der Klis FR, Vazquez JA. Effectiveness of meningococcal serogroup C vaccine programmes. Vaccine 2013; 31:4477-86; PMID:23933336; http://dx.doi.org/10.1016/j.vaccine.2013.07.083
10. A new MenB (Menincogoccal B) vaccine. [cited 2013 Aug]. Available from: http://www.meningitis.org/menb-vaccine.
11. Dinleyici EC, Ceyhan M. The dynamic and changing epidemiology of meningococcal disease at the country-based level: the experience in Turkey. Expert Rev Vaccines 2012; 11:515-8; PMID:22827237; http://dx.doi.org/10.1586/ erv.12.29
12. [cited 2013 August]. Available from: http://www.tuik.gov.tr/IcerikGetir. do?istab-id=21.
13. [cited 2013 August]. Available from: http://www.turkstat.gov.tr/ PreHaberBultenleri.do?id=15847.
14. Akyildiz B, Uzel N, Citak A, Soysal D, Karabocuoglu M, Ucsel R. The factors affecting mortality in meningococcal disease. Çocuk Saǧliǧi ve Hastaliklari Dergisi 2008;51:26-30.
15. Ceyhan M, Yildirim I, Balmer P, Borrow R, Dikici B, Turgut M, Kurt N, Aydogan A, Ecevit C, Anlar Y, et al. A prospective study of etiology of childhood acute bacterial meningitis, Turkey. Emerg Infect Dis 2008; 14:1089-96; PMID:18598630; http://dx.doi.org/10.3201/eid1407.070938
16. Ceyhan M, Celik M, Demir ET, Gurbuz V, Aycan AE, Unal S. Acquisition of meningococcal serogroup W-135 carriage in Turkish Hajj pilgrims who had received the quadrivalent meningococcal polysaccharide vaccine. Clin Vaccine Immunol 2013; 20:66-8; PMID:23136117; http://dx.doi.org/10.1128/CVI.00314-12
17. Bakir M, Toprak D, Soysal A, Türkoǧlu S, Turkish Bacterial Meningitis Surveillance Team. Serogroup determination of Neisseria meningiditis in bacterial meningitis: Turkish National Bacterial Meningitis Surveillance: 2006-2009. 29th Annual Meeting of the European Society for Paediatrics Infectious Diseases-ESPID, p229, Hague, Holland, 7-11 June 2011.
18. Cohn AC, Harrison LH. Meningococcal vaccines: current issues and future strategies. Drugs 2013; 73:1147-55; PMID:23839656; http://dx.doi.org/10.1007/ s40265-013-0079-2
19. Prevention and Control of Meningococcal Disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP). March 22, 2013 / 62(RR02);1-22. [cited: Jan 2013 Jan 10]. Available from: http://www.cdc.gov/ mmwr/preview/mmwrhtml/rr6202a1.htm
20. Advisory Committee on Immunization Practices (ACIP) Recommended Immunization Schedules for Persons Aged 0 Through 18 Years and Adults Aged 19 Years and Older - United States, 2013. MMWR Early Release / Vol. 62 January 28, 2013. Available from: http://www.cdc.gov/mmwr/pdf/wk/mm62e0128.pdf
21. Epidemiology and Prevention of Vaccine-Preventable Diseases. 12th Ed. Atkinson W, Wolfe C, Hamborsky J, editors. Meningococcal Disease 2012; 193-204.
22. Ceyhan M, Gurler N, Ozsurekci Y, et al. Meningitis caused by Neisseria meningitides, Haemophilus influenzae type B and Streptococcus pneumoniae during 2005-2011 in Turkey: Multicenter prospective study. 31st ESPID Meeting - Milan, Italy. May 28-June 1, 2013. Available from: http://w3.kenes-group.com/apps/ espid2013/abstracts/pdf/989.pdf
23. Wilder-Smith A, Chow A, Goh KT. Emergence and disappearance of W135 meningococcal disease. Epidemiol Infect 2010; 138:976-8; PMID:19845997; http://dx.doi.org/10.1017/S095026880999104X